1. Academic Validation
  2. Guanine modification of inhibitory oligonucleotides potentiates their suppressive function

Guanine modification of inhibitory oligonucleotides potentiates their suppressive function

  • J Immunol. 2013 Sep 15;191(6):3240-53. doi: 10.4049/jimmunol.1300706.
Franziska Römmler 1 Marion Jurk Eugen Uhlmann Monika Hammel Anna Waldhuber Lavinia Pfeiffer Hermann Wagner Jörg Vollmer Thomas Miethke
Affiliations

Affiliation

  • 1 Institut für Medizinische Mikrobiologie, Immunologie, und Hygiene, Technische Universität München, 81675 Munich, Germany.
Abstract

Inhibitory TLR7 and/or TLR9 Oligonucleotides (inhibitory oligonucleotide [INH-ODN]) are characterized by a phosphorothioate backbone and a CC(T)XXX₃₋₅GGG motif, respectively. INH-ODN 2088 is a prototypic member of this class of INH-ODN and acts as a TLR7 and TLR9 Antagonist. It contains a G quadruple that leads to higher order structures by the formation of G tetrads. These structures are unfavorable for the prediction of their pharmacological and immunological behavior. We show in this study that modification of Gs within the G quadruple by 7-deaza-guanine or 7-deaza-2'-O-methyl-guanine avoids higher order structures and improves their inhibitory potential. Whereas TLR9-induced TNF-α secretion of bone marrow-derived macrophages and conventional dendritic cells was equally inhibited by INH-ODN 2088 and G-modified INH-ODNs such as INH-ODN 24888, TLR7-induced TNF-α release and TLR7- and TLR9-induced IL-12p40 release were significantly more impaired by G-modified INH-ODNs. Similarly, the IL-6 release of B cells from wild-type and autoimmune MRL/Mp-lpr/lpr mice was more efficiently impaired by G-modified INH-ODNs. Surprisingly, INH-ODN 2088 stimulated B cells to proliferate when used in higher doses. Finally, in vivo, in wild-type and autoimmune MRL/Mp-lpr/lpr mice, G-modified INH-ODN 24888 was significantly more efficient than unmodified INH-ODN 2088. In summary, G modification allows the development of INH-ODNs with superior inhibitory potency for inflammatory diseases with high medical need such as systemic lupus erythematosus.

Figures